ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group’s perspective-Reference-Cited by-同舟云学术

ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group’s perspective

Published:2022-04 Issue:2 Volume:7 Page:100392
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Koessler T.,Alsina M.,Arnold D.,Ben-Aharon I.,Collienne M.,Lutz M.P.,Neuzillet C.,Obermannova R.,Peeters M.,Sclafani F.,Smyth E.,Valle J.W.,Wagner A.D.,Wyrwicz L.,Fontana E.,Moehler M.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference49 articles.

1. LBA7 Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study;Janjigian;Ann Oncol,2021

2. LBA54 Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): results of the randomized phase II INTEGA trial (AIO STO 0217);Stein;Ann Oncol,2021

3. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial;Bang;Lancet,2010

4. 1379P Margetuximab (M) with retifanlimab (R) in HER2+, PD-L1+ 1st-line unresectable/metastatic gastroesophageal adenocarcinoma (GEA): MAHOGANY cohort A;Catenacci;Ann Oncol,2021

5. LBA52 Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: first results of the phase III ORIENT-15 study;Shen;Ann Oncol,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Defining Tumor Microenvironment as a Possible Target for Effective GEP-NENs Immunotherapy—A Systematic Review;Cancers;2023-10-31